Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gossett, K. A.
Right arrow Articles by Dean, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gossett, K. A.
Right arrow Articles by Dean, J. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Clinical Pathologic Alterations Associated with Subcutaneous Administration of Recombinant Human Interleukin-4 to Cynomolgus Monkeys

Kent A. Gossett

Department of Toxicology, Drug Safety Assessment

Thomas A. Barbolt

Department of Toxicology, Drug Safety Assessment

Joel B. Cornacoff

Department of Toxicology, Drug Safety Assessment

David J. Zelinger

Department of Preclinical and Analytical Statistics, Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144

Jack H. Dean

Department of Toxicology, Drug Safety Assessment

Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 µg/kg/day for 28 days with a 14-day recovery to male and female cynomolgus monkeys as part of the preclinical safety evaluation. Clinical pathologic changes related to treatment with rhuIL-4 were evidence of consumptive coagulopathy, erythrocyte fragmentation, lymphocytosis, and lymphocyte morphologic changes indicative of marked antigenic or mitogenic stimulation, mild eosinophilia and neutrophilia, hypoalbuminemia, hypocholesterolemia, and hypertriglyceridemia. Based on data obtained after the 14-day recovery period, the clinical pathologic changes associated with rhuIL-4 administration were considered to be reversible.

Key Words: Toxicity • cancer • neoplasia • treatment • nonhuman primate • hematology • clinical chemistry

Toxicologic Pathology, Vol. 21, No. 1, 46-53 (1993)
DOI: 10.1177/019262339302100106
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
D. J. Herzyk, P. J. Bugelski, T. K. Hart, and P. J. Wier
Preclinical Safety of Recombinant Human Interleukin-18
Toxicol Pathol, August 1, 2003; 31(5): 554 - 561.
[Abstract] [PDF]